Timothy Eugene Sullivan Sells 10,287 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 10,287 shares of the stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total value of $223,947.99. Following the completion of the transaction, the chief financial officer directly owned 93,901 shares in the company, valued at approximately $2,044,224.77. This trade represents a 9.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Tuesday, January 20th, Timothy Eugene Sullivan sold 2,892 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $19.79, for a total transaction of $57,232.68.
• On Tuesday, January 13th, Timothy Eugene Sullivan sold 3,856 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $22.19, for a total transaction of $85,564.64.

Apellis Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ:APLS traded down $0.25 during trading on Friday, hitting $21.76. 2,214,978 shares of the company’s stock traded hands, compared to its average volume of 3,258,745. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The company has a 50-day moving average price of $22.99 and a 200-day moving average price of $23.49. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $30.91. The company has a market cap of $2.75 billion, a price-to-earnings ratio of 70.18 and a beta of 0.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The company had revenue of $458.58 million during the quarter, compared to the consensus estimate of $364.58 million. During the same quarter in the prior year, the firm earned ($0.46) earnings per share. The firm’s revenue was up 133.0% compared to the same quarter last year. As a group, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Institutional Trading of Apellis Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Simplify Asset Management Inc. bought a new position in shares of Apellis Pharmaceuticals during the 3rd quarter worth approximately $2,419,000. Corton Capital Inc. bought a new stake in Apellis Pharmaceuticals in the 2nd quarter valued at $364,000. Wealth Enhancement Advisory Services LLC lifted its holdings in Apellis Pharmaceuticals by 43.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 100,666 shares of the company’s stock valued at $1,838,000 after purchasing an additional 30,507 shares during the last quarter. Highland Capital Management LLC bought a new position in Apellis Pharmaceuticals during the third quarter worth $1,135,000. Finally, Schroder Investment Management Group boosted its position in Apellis Pharmaceuticals by 91.9% during the second quarter. Schroder Investment Management Group now owns 485,615 shares of the company’s stock worth $8,406,000 after purchasing an additional 232,506 shares during the period. Institutional investors own 96.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on APLS. Robert W. Baird upped their price objective on Apellis Pharmaceuticals from $50.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Mizuho cut their target price on Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. HC Wainwright cut their price objective on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. TD Cowen decreased their target price on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Finally, Needham & Company LLC cut their price target on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. Twelve analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.53.

Key Stories Impacting Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.